Overview

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

Status:
Enrolling by invitation

Trial end date:
2022-08-30

Target enrollment:

Participant gender:

Summary

This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.

Phase:

Phase 1

Details

Lead Sponsor:

Attralus, Inc.